What is the management and treatment approach for a patient diagnosed with a pituitary adenoma?

Management and Treatment of Pituitary Adenomas

Initial Diagnostic Evaluation

All patients with suspected pituitary adenoma require pre-contrast (T1 and T2) and post-contrast-enhanced thin-sliced pituitary MRI, including post-contrast volumetric sequences for increased sensitivity. 1, 2, 3

Neuroimaging Protocol

• Standard pituitary MRI protocol should include 2 mm slice, spin echo T1-weighted sequences before and after contrast, and fast or turbo spin echo T2-weighted sequences pre-contrast 1
• Consider 3-Tesla MRI for surgical planning as it enhances anatomical definition and may improve completeness of resection without altering complication rates 1, 4
• Intraoperative MRI may improve complete resection rates without increasing complications 1

Comprehensive Ophthalmologic Assessment

• Perform visual acuity testing (ideally logarithm of the minimum angle of resolution measurement), visual field testing (ideally Goldmann perimetry), and fundoscopy in all patients with suspected or confirmed pituitary adenoma 1, 4
• Visual assessment is critical because macroadenomas cause visual field defects in 18-78% of patients 5
• Baseline optical coherence tomography should be considered in patients with potentially severe acuity or field deficits 4

Endocrine Evaluation

• Complete endocrine evaluation must assess for hormone hypersecretion and hypopituitarism, which occurs in 34-89% of patients with macroadenomas 3, 5
• Evaluate gonadal, thyroid, and adrenal function as well as prolactin and growth hormone secretion in all patients 6
• Genetic assessment should be offered to all patients, particularly children and young people who have higher likelihood of underlying genetic disease 3

---

Treatment Approach Based on Adenoma Type

Prolactinomas (Most Common: 32-66% of adenomas)

Dopamine agonists (cabergoline or bromocriptine) are first-line treatment for prolactinomas, even for macroadenomas with visual compromise. 3, 5, 7

• Cabergoline and bromocriptine are the primary medical therapies 5, 7
• Effects on visual disturbances are often very rapid (within hours or days) and tumoral shrinkage is usually very significant 6
• Prolactin levels should be assessed at 3-6 month intervals initially 3
• Surgery is reserved for patients who fail medical therapy or cannot tolerate dopamine agonists 7

Non-Functioning Pituitary Adenomas (15-54% of adenomas)

Transsphenoidal surgery is the treatment of choice for non-functioning adenomas when the patient is symptomatic, the visual pathway is threatened, or there is interval tumor growth on MRI. 2, 3

• Asymptomatic incidental macroadenomas without visual compromise may be managed with MRI surveillance 2
• Small incidentally discovered microadenomas may be carefully followed without immediate therapy 6, 8
• Post-operative MRI surveillance should be performed at 3 and 6 months, and 1,2,3, and 5 years after surgery 2, 3

Growth Hormone-Secreting Adenomas (8-16% of tumors)

Transsphenoidal surgery is first-line therapy for growth hormone-secreting adenomas. 3, 7

• Surgery is the primary treatment except when the macroadenoma is giant or surgery is contraindicated 6
• Somatostatin analogs (now available in slow-release form) are used when surgery is contraindicated, has failed to normalize GH levels, or while waiting for delayed effects of radiation therapy 6
• If probability of surgical cure is low (very large and/or invasive tumors), somatostatin analogs may be reasonable primary therapy provided the tumor does not threaten vision or neurological function 6
• Pegvisomant (GH-receptor antagonist) is indicated in cases of resistance to somatostatin analogs 6

ACTH-Secreting Adenomas (Cushing Disease: 2-6% of adenomas)

Primary therapy is transsphenoidal surgery by a skilled surgeon, whether or not a microadenoma is visible on MRI. 7, 6

• Late-night salivary cortisol level is the best screening test 7
• Petrosal sinus sampling for ACTH may be necessary to distinguish pituitary from ectopic source 7
• Medical therapies including ketoconazole, mifepristone, and pasireotide are used for patients not cured by surgery 7
• Radiotherapy is reserved for patients who are subtotally resected or remain hypersecretory after surgery 6
• Adrenal steroidogenesis inhibitors (mitotane, ketoconazole) may be indicated while waiting for effects of radiotherapy 6
• Bilateral adrenalectomy may be proposed if drugs are not available or not tolerated 6

TSH-Secreting Adenomas (1% of tumors)

First-line therapy is transsphenoidal surgery, with pituitary radiotherapy considered for patients with post-operative tumor remnant and resistance to medical therapy. 3

• Somatostatin analogs are used if not surgically cured 7, 6

---

Post-Treatment Surveillance and Follow-Up

Visual Assessment

• Visual assessment (acuity and fields) should be performed within 3 months of first-line therapy for all patients with pituitary macroadenoma 2, 4
• Ongoing visual follow-up should be based on individual indications 2, 4

Imaging Surveillance

• For non-functioning macroadenomas, MRI surveillance at 3 and 6 months, and 1,2,3, and 5 years post-operatively 2, 3
• While radiological surveillance of stable non-functioning microadenomas can cease after 1-3 years, macroadenomas need long-term follow-up 2
• Unenhanced T1-weighted and T2-weighted MRI sequences should be considered during follow-up in pediatric patients to minimize gadolinium exposure 1

Hormone Monitoring

• Regular hormone level assessments specific to the tumor type should be conducted during follow-up 2, 3
• Hypopituitarism is common in patients with macroadenomas and may require hormone replacement therapy 2, 3

---

Peri-operative Management

Fluid and Electrolyte Monitoring

• Strict fluid and electrolyte balance monitoring is essential peri-operatively and post-operatively for all patients undergoing pituitary surgery 2
• Post-operative complications may include diabetes insipidus (26%) and SIADH (14%) 2

---

Special Considerations for Children and Adolescents

Unique Characteristics

• Pituitary adenomas in children tend to have more occult presentation, aggressive behavior, and are more likely to have a genetic basis than in adults 3
• Visual disturbances are more common in pediatric patients with pituitary adenomas than in adults 4
• Treatment impacts can affect development and have lifelong consequences 2

Management Approach

• Treatment should be managed by a multidisciplinary team with experts from both pediatric and adult practice 3
• Boys with Cushing disease tend to have more aggressive disease with elevated BMI, shorter height, and higher plasma ACTH levels than girls 3
• Patient support groups offer educational resources and support communities that highlight unique challenges affecting this developmental age group 1

---

Common Pitfalls and Caveats

Diagnostic Pitfalls

• Mild hyperprolactinemia can be caused by stalk compression from macroadenomas and does not necessarily indicate a prolactinoma 3
• Visual field defects may be present even when patients are asymptomatic, highlighting the need for comprehensive ophthalmologic evaluations 4
• Many patients may be unaware of visual field deficits, emphasizing the importance of formal testing 4

Prognostic Considerations

• Older patients and those with longer duration (>4 months) of vision loss should be counseled regarding reduced chance of postoperative vision improvement 4
• Early detection of visual field deficits is important for timely intervention 4

Gadolinium Considerations

• Low-level gadolinium deposits in the dentate nucleus and globus pallidus have unknown neurological impact 1
• Macrocyclic or newer linear gadolinium-containing contrast agents should be used in weight-adapted doses 1
• In patients with estimated glomerular filtration rate <30 ml/min/1.73 m² or on dialysis, gadolinium administration should be considered individually with alternative imaging modalities utilized whenever possible 1